CytomX Therapeutics, Inc. Financing Cash Flow
CytomX Therapeutics, Inc. (CTMX) reported Financing Cash Flow of $235.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- CytomX Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $511.00K, a 99.45% decline year-over-year.
- CytomX Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $234.49M.
- CytomX Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $16.64M, a 640.02% increase year-over-year.
- CytomX Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $253.00K.
- CytomX Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $110.45M, a 1368.31% increase from fiscal 2024.
- CytomX Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $7.52M, a 75.12% decline from fiscal 2023.
- CytomX Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $30.23M, a 4565.12% increase from fiscal 2022.
- CytomX Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $648.00K, a 99.41% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $511.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $235.00M 10-Q · filed 2026-08-06 | $251.64M derived: sum of 3 quarters · filed 2026-08-06 | $251.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $234.49M 10-Q · filed 2026-05-07 | $251.13M derived: sum of 2 quarters · filed 2026-05-07 | $251.38M derived: sum of 3 quarters · filed 2026-05-07 | $344.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $16.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $16.90M derived: sum of 2 quarters · filed 2026-03-16 | $110.45M derived: sum of 3 quarters · filed 2026-08-06 | $110.45M 10-K · filed 2026-03-16 |
| 2025-09-30 | $253.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $93.80M derived: sum of 2 quarters · filed 2026-08-06 | $93.80M 10-Q · filed 2025-11-06 | $96.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $93.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $93.55M 10-Q · filed 2026-08-06 | $95.80M derived: sum of 3 quarters · filed 2026-08-06 | $95.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $2.25M derived: sum of 2 quarters · filed 2026-05-07 | $2.25M derived: sum of 3 quarters · filed 2026-05-07 | $7.35M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.25M derived: sum of 2 quarters · filed 2026-03-16 | $7.35M derived: sum of 3 quarters · filed 2026-03-16 | $7.52M 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.10M derived: sum of 2 quarters · filed 2025-11-06 | $5.27M 10-Q · filed 2025-11-06 | $5.52M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.27M 10-Q · filed 2025-08-07 | $5.52M derived: sum of 3 quarters · filed 2025-08-07 | $35.19M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $174.00K 10-Q · filed 2025-05-12 | $418.00K derived: sum of 2 quarters · filed 2025-05-12 | $30.09M derived: sum of 3 quarters · filed 2025-05-12 | $30.40M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $29.91M derived: sum of 2 quarters · filed 2025-03-06 | $30.23M derived: sum of 3 quarters · filed 2025-03-06 | $30.23M 10-K · filed 2025-03-06 |
| 2023-09-30 | $29.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $29.99M derived: sum of 2 quarters · filed 2024-11-07 | $29.99M 10-Q · filed 2024-11-07 | $30.18M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $317.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $317.00K 10-Q · filed 2024-08-08 | $507.00K derived: sum of 3 quarters · filed 2024-08-08 | $507.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $190.00K derived: sum of 2 quarters · filed 2024-05-08 | $190.00K derived: sum of 3 quarters · filed 2024-05-08 | $641.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $190.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $190.00K derived: sum of 2 quarters · filed 2024-03-11 | $641.00K derived: sum of 3 quarters · filed 2024-03-11 | $648.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $451.00K derived: sum of 2 quarters · filed 2023-11-07 | $458.00K 10-Q · filed 2023-11-07 | $1.14M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $451.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $458.00K 10-Q · filed 2023-08-08 | $1.14M derived: sum of 3 quarters · filed 2023-08-08 | $1.25M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $7.00K 10-Q · filed 2023-05-09 | $690.00K derived: sum of 2 quarters · filed 2023-05-09 | $794.00K derived: sum of 3 quarters · filed 2023-05-09 | $1.49M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $683.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $787.00K derived: sum of 2 quarters · filed 2023-03-27 | $1.48M derived: sum of 3 quarters · filed 2023-03-27 | $110.21M 10-K/A · filed 2023-03-27 |
| 2021-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $795.00K derived: sum of 2 quarters · filed 2022-11-08 | $109.53M 10-Q · filed 2022-11-08 | $122.55M derived: sum of 4 quarters · filed 2023-03-27 |
| 2021-06-30 | $691.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $109.43M 10-Q · filed 2022-08-04 | $122.45M derived: sum of 3 quarters · filed 2023-03-27 | $122.61M derived: sum of 4 quarters · filed 2023-03-27 |
| 2021-03-31 | $108.73M 10-Q · filed 2022-05-05 | $121.76M derived: sum of 2 quarters · filed 2023-03-27 | $121.92M derived: sum of 3 quarters · filed 2023-03-27 | $123.47M derived: sum of 4 quarters · filed 2023-03-27 |
| 2020-12-31 | $13.02M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $13.19M derived: sum of 2 quarters · filed 2023-03-27 | $14.74M derived: sum of 3 quarters · filed 2023-03-27 | $16.89M 10-K/A · filed 2023-03-27 |
| 2020-09-30 | $167.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.72M derived: sum of 2 quarters · filed 2021-11-04 | $3.87M 10-Q · filed 2021-11-04 | $4.27M derived: sum of 4 quarters · filed 2023-03-27 |
| 2020-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.71M 10-Q · filed 2021-08-05 | $4.11M derived: sum of 3 quarters · filed 2023-03-27 | $4.17M derived: sum of 4 quarters · filed 2023-03-27 |
| 2020-03-31 | $2.16M 10-Q · filed 2021-05-06 | $2.56M derived: sum of 2 quarters · filed 2023-03-27 | $2.62M derived: sum of 3 quarters · filed 2023-03-27 | $3.32M derived: sum of 4 quarters · filed 2023-03-27 |
| 2019-12-31 | $401.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $464.00K derived: sum of 2 quarters · filed 2023-03-27 | $1.16M derived: sum of 3 quarters · filed 2023-03-27 | $1.63M 10-K/A · filed 2023-03-27 |
| 2019-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $761.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.23M 10-Q · filed 2020-11-05 | $1.95M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $698.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.16M 10-Q · filed 2020-08-06 | $1.89M derived: sum of 3 quarters · filed 2021-02-24 | $137.46M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $465.00K 10-Q · filed 2020-05-07 | $1.19M derived: sum of 2 quarters · filed 2021-02-24 | $136.76M derived: sum of 3 quarters · filed 2021-02-24 | $137.49M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $724.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $136.30M derived: sum of 2 quarters · filed 2021-02-24 | $137.02M derived: sum of 3 quarters · filed 2021-02-24 | $139.62M 10-K · filed 2021-02-24 |
| 2018-09-30 | $135.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $136.30M derived: sum of 2 quarters · filed 2019-11-07 | $138.90M 10-Q · filed 2019-11-07 | $159.98M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $722.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $3.32M 10-Q · filed 2019-08-07 | $24.40M derived: sum of 3 quarters · filed 2020-02-27 | $25.56M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $2.60M 10-Q · filed 2019-05-09 | $23.68M derived: sum of 2 quarters · filed 2020-02-27 | $24.84M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | $21.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $22.24M derived: sum of 2 quarters · filed 2020-02-27 | $23.80M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $2.72M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $1.56M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | $996.00K 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |